Edition:
United Kingdom

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

8.70USD
6:10pm GMT
Change (% chg)

$-0.20 (-2.25%)
Prev Close
$8.90
Open
$9.25
Day's High
$9.25
Day's Low
$8.70
Volume
36,469
Avg. Vol
32,456
52-wk High
$16.15
52-wk Low
$6.15

Chart for

About

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe... (more)

Overall

Beta: 2.57
Market Cap(Mil.): $107.52
Shares Outstanding(Mil.): 8.37
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.

16 Jan 2018

UPDATE 2-Eiger to abandon blood pressure drug after trial failure

* Shares slump about 46 pct in morning trading (Adds details on company's pipeline, CEO's and analyst comment, background on PAH; updates share movement)

16 Jan 2018

Eiger BioPharma abandons blood pressure drug after failed study

Jan 16 Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

16 Jan 2018

BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal

* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT

16 Jan 2018

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

11 Dec 2017

BRIEF-‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​

* ‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:

09 Nov 2017

BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.10

* Eiger Biopharmaceuticals reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Eiger Biopharmaceuticals closes public offering

* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:

31 Oct 2017

BRIEF-EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

27 Oct 2017

BRIEF-Eiger BioPharmaceuticals announces proposed public offering of common stock

* Eiger BioPharmaceuticals announces proposed public offering of common stock

26 Oct 2017

Earnings vs. Estimates